Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone vs spectinomycin for uncomplicated genital gonorrhoea (ChiCTR2100050261)
ChiCTR2100050261Phase 4Not yet recruiting
- Sponsor
- Institute of Dermatology, Chinese Academy of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in gonorrhea comparing ceftriaxone control group with spectinomycin treatment group (2 arms). Primary endpoint: Etiological efficacy (microbiological cure). Planned start Sep 2021; status: not yet recruiting.
02
Drugs
ceftriaxonespectinomycin
03
Conditions
gonorrhea
Beyond the preview
Go deeper on ChiCTR2100050261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050261.